Clinical trials of ROCK inhibitors
| Indication | Compound | Target | Phase | Status | Identifier |
|---|---|---|---|---|---|
| Glaucoma | AMA0076 | ROCK1/ROCK2 | 2 | Completed | NCT02136940; NCT01693315; NCT02003547 |
| PG324 | ROCK1/ROCK2 | 2 | Completed | NCT025057575 | |
| Y-39983 (SNJ-1656; RKI-983) | ROCK1/ROCK2 | 2 | Completed | NCT00846989; NCT00515424 | |
| AR-13324 | ROCK1/ROCK2 | 3 | Recruiting | NCT02207621 | |
| Psoriasis | KD025 (SLx2119) | ROCK2 | 2 | Recruiting | NCT02317627 |
| 2 | Completed | NCT02106195 | |||
| Diabetic retinopathy | K-115 (Ripasudil) | ROCK1/ROCK2 | 2 | Completed | JapicCTI-142456 |
| Fasudil | ROCK1/ROCK2 | 3 | Recruiting | NCT01823081 | |
| Erectile dysfunction | SAR407899 | ROCK1/ROCK2 | 2 | Completed | NCT00914277 |
| Amyotrophic lateral sclerosis | Fasudil | ROCK1/ROCK2 | 2 | Recruiting | NCT01935518 |
| Spinal cord injury | Fasudil | ROCK1/ROCK2 | 1/2 | Completed | JPRN-UMIN000000825 |
| Atherosclerosis | Fasudil | ROCK1/ROCK2 | 2 | Completed | NCT00120718 |
| Fasudil | ROCK1/ROCK2 | 2 | Recruiting | NCT00670202 | |
| Chronic kidney disease | SAR407899 | ROCK1/ROCK2 | 1 | Completed | NCT01485900 |